Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICCOLO phase 2 study of mirvetuximab soravtansine in recurrent platinum-sensitive ovarian-related cancers with high FRα expression
2021-003592-34Phase 2Active
- Sponsor
- ImmunoGen
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by ImmunoGen. Primary endpoint: Objective response rate. Started Oct 2021; status: active.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2021-003592-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003592-34.